The leading stocks led the market. These include WuXi PharmaTech, Mindray Medical and zhifei Bio. These enterprises, with their strong R&D strength, leading technical level and stable performance, have become the hot targets of investors' attention. What are the leading stocks brought by the following small series to the relevant medical sectors? This will do you a lot of good. Let's have a look.
What are the leading stocks in the medical sector?
1. General medicine faucet: 600276 Hengrui Pharma.
Hengrui Pharma is a large pharmaceutical listed company integrating scientific research, production and sales, the largest research and production base of anti-tumor drugs and surgical drugs in China, and one of the most innovative large pharmaceutical enterprises in China at present. The company's main products are anti-tumor drugs, cardiovascular drugs, surgical drugs, endocrine drugs and so on.
2. General faucet of traditional Chinese medicine: 000538 Yunnan Baiyao
Yunnan Baiyao Group Co., Ltd., formerly known as Yunnan Baiyao Factory, was founded in 197 1. It is the largest pharmaceutical enterprise group with the strongest strength and the best brand in Yunnan Province. The company's business includes the research, production and sales of chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines, biological products, health foods, cosmetics and beverages; But also relates to the field of medical devices and daily chemical products.
3. Blood products faucet: 002007 Hualan Bio
Founded in 1992, Hualan Bio is a national key high-tech enterprise engaged in the research and development and production of blood products. From 65438 to 0998, Hualan Bio became the first enterprise in China to pass GMP certification in blood products industry. As a national designated large-scale biological product manufacturer, Hualan is in a leading position among domestic enterprises in the same industry with its strong biotechnology development strength, leading technical level, first-class production and testing equipment, scientific and standardized management and perfect quality assurance system.
4. Vaccine faucet: 300 122 Zhifei creature.
Zhifei Bio is a high-tech company mainly engaged in biotechnology development and management, integrating scientific research, production and sales.
5. Pharmaceutical R invested in the establishment of Sanye Children's Oral Chain Operation Co., Ltd. to locate the middle and high-end children's oral market segment.
2. Aier Ophthalmology (3000 15): the leading medical service. The third quarterly report of Aier Ophthalmology 2002/KLOC-0 shows that the total operating income increased by -3.48% year-on-year to 4.248 billion yuan, and the net profit increased by 2.05% year-on-year to 888 million yuan. 20 13, Aier Eye Hospital Group and Central South University jointly established a professional ophthalmology medical college-Aier Eye College of Central South University, which mainly trains senior medical talents with master's and doctoral degrees in ophthalmology; 20 14 Once again, Aier Eye Research Institute was jointly established with Hubei University of Science and Technology.
3. Guo Xin Health (000503): It is a state-owned enterprise in the medical service industry.
4.ST Huasu (000509): The company's main business, medical services and commodity trade. International Medicine (0005 16):20 15 In April, the company signed a strategic cooperation agreement with Alibaba Cloud and Donghua Software to build the first domestic entity "Future Hospital" Xi 'an International Medical Center, which is also the first domestic entity medical institution with data-driven precision medical treatment and health management.
5. Jinling Pharmaceutical (0009 19): 1. Pharmaceutical production and sales business, which refers to the production of proprietary Chinese medicines and chemicals; Drug sales business refers to the sales of self-produced drugs and agents of drugs and medical devices.
What are the leading stocks of Chinese medicine stocks?
1 Pien Tze Huang
2 Yunnan Baiyao
3 Jiuzhitang
4 Tongrentang
5 Baiyun Mountain
6 Jiang Zhong drugstore
7 Ma Yinglong
What are the leading stocks of medical and American listed companies?
1, Huaxi Bio: medical beauty leading stock. Huaxi Bio's latest offer 164.65 yuan, the share price fell by 0.23% within 7 days. Since the beginning of this year, the growth rate has dropped by-12.85%, and the price-earnings ratio is 12 1.96. The world's leading high-tech enterprise with hyaluronic acid microbial fermentation production technology as its core, the industrialization scale of hyaluronic acid ranks in the forefront of the world, and the company is one of the earliest enterprises in China to produce hyaluronic acid by microbial fermentation; In June 2020, the company plans to acquire 0/00% equity of Dongying Foster/KLOC for 290 million yuan. Foster is mainly engaged in the production and sales of hyaluronic acid raw materials, and has built a leading domestic production device for hyaluronic acid series products.
2. Aimeike: medical beauty leading stock. Aimeike's latest offer is 565.9 1 yuan, and its share price has dropped by 0.59% within 7 days. Since the beginning of this year, the growth rate has dropped by-13. 13%, and the price-earnings ratio is 125.54. Domestic hyaluronic acid faucet for injection, the revenue of solution injection products accounted for 63.07%, among which explosive products performed strongly, and the overall gross profit margin was as high as 92. 17%, which was higher than that of Maotai, and it was the leading stock of pure medical beauty.
3. International medicine: According to the investor interaction platform, up to now, the projects under construction of the company are mainly rehabilitation hospital projects. The medical beauty, orthopedics and reproductive business that the company has carried out belongs to listed companies.
4. Aoyuan Meigu: The company will explore high-end textile, medical beauty, health care and other application fields with green fiber as the link, especially relying on the strategic layout of controlling shareholder China Aoyuan Group in Shanghai Oriental Meigu (one of the domestic medical beauty, cosmetics and health industry bases).
5. suning universal: It is estimated that the net profit of Medical Beauty will be 50 million+in the next 2-3 years. At present, these four institutions have not merged. The company's net profit for returning to the mother in 2022 is expected to be 65.438+0.5 billion yuan, accounting for 3.3%. Huashen Technology: The project of Medical Beauty Hospital is still in progress.
6. Dezhan Health: Hanting Bio, a holding subsidiary of the company, develops, produces and sells medical beauty products.
7. Tongce Medical (600763): the leader of medical services. Total operating income of Tongce Medical in the third quarter of 2002/KLOC-0 increased by 14.62% to 8190,000 yuan. It owns Kunming Maternal and Child Health Reproductive Medicine Hospital Co., Ltd., which is mainly engaged in assisted reproductive medical services; Invest in the establishment of Sanye Children's Oral Chain Management Co., Ltd. to locate the middle and high-end children's oral market segment.
Leading stocks in the health care sector
Hengrui pharmacy
600276
Shanghai stock market
Chemical pharmacy
It is the pioneer and leader of innovative drug research and development in China. The company is a leading company in the field of innovative drugs in China, with a complete product structure and R&D channels. Leading the research and development of innovative drugs. Pirotinib is independently developed by the company 1. An innovative drug is the company's blockbuster product. The indication market of pirotinib for breast cancer is $65.438+$400 million, and its indication will be extended to lung cancer and gastric cancer in the future.
Fosun Pharma
600 196
Shanghai stock market
Biopharmaceutical Ⅱ
Fu Honghanlin is a biopharmaceutical R&D and production platform with 6 1.093 shares. The research and development strength and progress of biosimilars are in a leading position in China. It is expected that biosimilars such as rituximab, trastuzumab and adalimumab will be approved in the next three years. The biosimilars market is large, with many heavyweight products, high entry threshold and low medical insurance support. In the long run, they are optimistic about the oligopoly competition model.
Yunnan Baiyao
000538
Shen Shi
Traditional Chinese medicine Ⅱ
This company is one of the famous manufacturers of Chinese patent medicines in China. It is one of the top 50 Chinese patent medicine enterprises. The company's main products are Yunnan Baiyao and natural plant medicine, with dosage form 19, more than 300 varieties, and the sales volume ranks first in Yunnan Province. At present, the company also has Yunnan Baiyao powder and Yunnan Baiyao capsule, which are national first-class protected Chinese patent medicines. On August 20 17 18, Yunnan Baiyao was selected into the health brand list and brand value list of China on August 20 17.
Xinlitai
002294
Small and medium plate
Chemical pharmacy
The internal and external expansion of Shenzhen Lee Tae Pharmaceutical Co., Ltd. is the dual strength of the medical equipment echelon. The company focuses on the development of cardiovascular special drugs, innovative drugs and unique products. Existing patented drugs have unique advantages, forming a pyramid product structure from high-end radiation to downward radiation. The innovative drugs are progressing smoothly, and the clinical use of compound gliptin is in progress. A new anti-heart failure drug S glucagon-like peptide-1-Fc injection fusion protein has been accepted.
Klein
600 166
Shanghai stock market
Chemical pharmacy
Gloria Pharmaceutical Group (Tianjin) Co., Ltd. is committed to the technological innovation and commercial utilization of global pharmaceutical technology, and provides comprehensive pharmaceutical outsourcing services for international mainstream pharmaceutical companies. Its scope mainly includes the development, preparation and marketing of new drugs in clinical stage. Process optimization and mass production are carried out in the commercialization stage. Domestic CMO provides 1. 1 new drug research and development services to many domestic pharmaceutical companies through CDMO. Represents new drugs: treating hepatitis C, cardiovascular diseases, gallbladder fibers, etc.
Aier ophthalmology
6004 18
Shanghai stock market
medical service
This company is one of the largest ophthalmic medical institutions in China. Aier Eye Hospital Group Co., Ltd. is an ophthalmic medical institution. The company mainly provides ophthalmic medical services for patients, such as diagnosis, treatment, optometry and glasses of various ophthalmic diseases. In 2008 and 2009, the company stood out among the most valuable companies in China in 2008 and 2009, and was selected as one of the top 50 most valuable companies with zero technology in China for two consecutive years.
Pien Tze Huang
600436
Shanghai stock market
Traditional Chinese medicine Ⅱ
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. is a company mainly producing and selling tablets, tablets, granules and other medical products and tourism products. At present, the main business is the production and sales of traditional Chinese medicine. In recent years, daily necessities and cosmetics have grown rapidly. The company's new strategy of one core and two wings is based on the production of traditional Chinese medicine, with health care drugs, health food, functional drinks, special cosmetics and daily chemical products as the wings, supplemented by drug circulation. Based on Pien Tze Huang, a strong brand with a history of 100 years, the company will open the road to the future growth of branded Chinese medicine consumer goods.